Acticor Biotech adds Leila Nicolas to its Board along with raising €7m additional funding led by Go Capital

– FRANCE, Paris –  Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced that it has raised €7 million in addition to its Series B which is now completed at €22,3 million. This additional funding will enable the company to expand ACTIMIS, a phase II trial in acute ischemic stroke with its lead candidate glenzocimab in the US.

The financing was led by a new investor Go Capital. Existing investors Newton BioCapital, CapDecisif Management and Anaxago also participated in this additional funding.

Simultaneously as closing its Series B financing, Acticor Biotech acquired 100% of AVCare’s shares. AVCare is a start-up diagnostic company, founded by Pr. Serge Timsit and Jean-Marc Herbert and financed by SATT Ouest Valorisation and Go Capital, which is developing a stroke blood biomarker. Acticor Biotech and SATT Ouest Valorisation enter into a sub-licensing agreement which gave worldwide rights to Acticor to develop and exploit the stroke biomarker.

Leila Nicolas, Investment Director of Go Capital will now join the Board of Directors of Acticor Biotech and she commented: “It was a very good opportunity for AVCare to be integrated into a promising biotech such as Acticor. We are also excited to participate into the financing of Acticor Biotech and look forward to getting the results of the phase II clinical development in acute ischemic stroke as well as expanding it into the US.”

Gilles Avenard, President of Acticor Biotech, added: “We are delighted to have raised additional equity from specialised healthcare investors who will enable us to expand our ongoing Phase II, ACTIMIS, in the US. Our pre-IND consultation with the FDA in the summer was encouraging enough to take the decision to file an IND in the coming months.”About GO Capital

GO Capital is an independent venture capital firm that invests primarily in high- tech companies located in Western and Central France, in the fields of Digital Economy, Life Sciences, Eco technologies and Service Innovation. GO CAPITAL invests in companies via several funds, from their creation to their expansion worldwide, in order to boost their development.

For more information:

About Acticor Biotech

Acticor Biotech is a clinical-stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke. Acticor Biotech is built upon the expertise and the results of research conducted by the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.